BTIG Maintains Buy on Bicara Therapeutics, Lowers Price Target to $37
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $39 to $37.
BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $39 to $37.